improv
use
highli
pure
antigen
improv
vaccin
safeti
led
reduc
vaccin
immunogen
efficaci
led
need
use
adjuv
improv
vaccin
immunogen
ideal
adjuv
maxim
vaccin
immunogen
without
compromis
toler
safeti
pose
undu
risk
unfortun
adjuv
research
lag
behind
vaccin
area
antigen
discoveri
consequ
limit
number
adjuv
base
aluminum
salt
monophosphoryl
lipid
oil
emuls
current
approv
human
use
recent
strateg
initi
support
adjuv
develop
nation
institut
health
translat
greater
adjuv
choic
futur
mechanist
studi
valuabl
better
understand
adjuv
action
mechan
adjuv
toxic
less
well
understood
inflammatori
dangersign
model
adjuv
action
impli
increas
vaccin
reactogen
inevit
price
improv
immunogen
henc
adjuv
reactogen
may
avoid
possibl
separ
inflamm
adjuv
action
biggest
remain
challeng
adjuv
field
deciph
potenti
relationship
adjuv
rare
vaccin
advers
reaction
narcolepsi
macrophag
myofasci
alzheim
diseas
exist
adjuv
base
aluminum
salt
strong
safeti
record
ongo
need
new
adjuv
intens
research
adjuv
effect
tradit
vaccin
whole
cell
pertussi
whole
viru
influenza
vaccin
highli
immunogen
albeit
price
signific
local
system
reactogen
reduc
reactogen
modern
approach
incorpor
split
subunit
recombin
antigen
reactogen
contamin
lipopolysaccharid
dna
rna
remov
highlight
acellular
pertussi
vaccin
improv
safeti
subunit
vaccin
come
price
reduc
immunogen
move
subunit
vaccin
also
result
case
shift
balanc
vaccin
respons
respons
revers
whole
cell
vaccin
approach
could
improv
immunogen
would
also
recreat
excess
reactogen
incomplet
viru
split
manufactur
found
respons
excess
hospit
febril
convuls
caus
recent
withdrawn
pediatr
inactiv
influenza
vaccin
therebi
highlight
tradeoff
thu
close
relationship
vaccin
immunogen
reactogen
aris
contamin
lipopolysaccharid
dna
rna
contain
whole
cell
vaccin
act
inbuilt
adjuv
reactogen
properti
reflect
abil
contamin
induc
inflamm
via
activ
innat
immun
receptor
consequ
adjuv
action
reactogen
insepar
doselimit
reaction
includ
local
swell
pain
plu
system
fever
malais
adjuv
reactogen
therebi
regard
dosedepend
phenomena
reflect
local
tissu
damag
system
inflamm
induc
activ
innat
immun
receptor
adjuv
induc
excess
reactogen
vaccin
problem
solv
lower
dose
reactogen
compon
combin
adjuv
vaccin
formul
could
regard
potenti
unsaf
although
even
context
depend
exampl
withdrawn
pediatr
influenza
vaccin
mention
still
regard
safe
remain
approv
use
older
individu
risk
febril
convuls
therebi
highlight
extrem
complex
vaccin
safeti
assess
even
greater
challeng
adjuv
safeti
assess
focus
chanc
immedi
advers
effect
pain
swell
fever
assess
adjuv
risk
refer
rel
possibl
develop
adjuvantassoci
problem
life
individu
immun
henc
challeng
aspect
assess
adjuv
risk
determin
basi
lack
thereof
variou
report
associ
use
vaccin
contain
specif
adjuv
develop
rare
autoimmun
chronic
degen
disord
exampl
associ
use
squalen
emuls
adjuv
vaccin
narcolepsi
gulf
war
syndrom
use
aluminum
adjuv
macrophag
myofasci
alzheim
diseas
assess
made
exceedingli
difficult
pauciti
data
inabl
control
studi
human
prove
causat
potenti
extrem
long
time
period
immun
onset
symptom
henc
causat
vast
major
case
never
establish
leav
uncertainti
whether
associ
might
real
link
chanc
thu
great
need
better
research
tool
probe
natur
associ
review
focu
current
adjuv
least
reach
stage
human
clinic
trial
test
identifi
known
still
learn
aspect
adjuv
safeti
articl
identifi
pubm
use
key
word
term
vaccin
adjuv
safeti
vaccin
adjuv
toxic
focu
articl
publish
last
year
human
adjuv
publish
clinic
trial
data
includ
steril
abscess
lymphadenopathi
chronic
skin
ulcer
review
local
vaccin
side
effect
may
reflect
direct
chemic
irrit
due
nonphysiolog
ph
osmolar
salt
concentr
direct
cell
toxic
local
irrit
effect
typic
associ
immedi
sever
inject
site
pain
follow
inflammatori
respons
trigger
tissu
damag
exampl
adjuv
induc
local
reactogen
includ
saponin
eg
quil
iscom
iscomatrix
oil
emuls
eg
complet
freund
adjuv
incomplet
freund
adjuv
montanid
immedi
reaction
like
reflect
irrit
inflamm
induc
adjuv
compon
delay
hour
may
reflect
excess
delay
type
hypersensit
dth
respons
vaccin
compon
alreadi
prime
individu
local
reactogen
life
threaten
could
still
lead
signific
morbid
eg
worst
steril
abscess
need
surgic
drainag
skin
ulcer
requir
skin
graft
local
reaction
sever
pain
directli
damag
physic
health
may
still
strongli
impact
neg
public
percept
riskbenefit
immun
henc
avoid
ground
system
reactogen
typic
includ
symptom
fever
headach
malais
nausea
diarrhea
arthralgia
myalgia
lethargi
larg
reflect
adjuvantassoci
innat
immun
activ
downstream
inflamm
adjuv
strongli
activ
innat
immun
receptor
eg
adjuv
base
pathogenassoci
molecular
pattern
pamp
may
therebi
prone
system
reactogen
includ
tolllik
receptor
tlr
ligand
monophosphoryl
lipid
mpl
flagellin
lipoarabinomannan
peptidoglycan
acyl
lipoprotein
review
system
reactogen
also
issu
adjuv
induc
local
tissu
damag
eg
oil
emuls
saponin
result
releas
endogen
damageassoci
molecular
pattern
damp
activ
innat
immun
receptor
induc
inflamm
typic
inflammationassoci
adjuv
reactogen
would
expect
settl
innat
immun
respons
subsid
could
potenti
last
sever
week
postimmun
seriou
end
adjuv
system
toxic
spectrum
potenti
rare
immunolog
toxic
result
aberr
immun
activ
driven
adjuv
includ
problem
immun
bia
eg
eosinophilia
allerg
reaction
anaphylaxi
caus
bia
impart
aluminum
adjuv
also
includ
potenti
adjuv
induc
chronic
immun
activ
inflamm
settl
postimmun
exampl
would
syndrom
macrophag
myofasci
wherebi
longlast
tissu
depot
aluminum
adjuv
link
symptom
chronic
fatigu
syndrom
although
discuss
later
associ
question
bodi
global
advisori
committe
vaccin
safeti
gacv
final
risk
adjuv
may
either
act
trigger
increas
likelihood
vaccin
caus
autoimmun
diseas
exampl
abil
inflammatori
oil
emuls
adjuv
induc
adjuv
arthriti
geneticallysuscept
anim
model
adjuvantassoci
immun
dysregul
potenti
caus
autoimmun
disord
repres
wide
debat
aspect
adjuv
risk
assess
spontan
autoimmun
condit
affect
small
number
geneticallysuscept
individu
gener
popul
henc
even
vaccineadjuv
combin
thought
caus
autoimmun
diseas
would
hard
prove
particularli
everyon
popul
receiv
vaccin
case
narcolepsi
pandem
influenza
vaccin
except
singl
vaccin
use
across
discret
period
time
everyon
vaccin
good
control
group
avail
show
use
particular
vaccin
almost
certainli
caus
increas
risk
diseas
also
includ
within
spectrum
potenti
adjuv
system
toxic
potenti
chronic
organ
toxic
compound
exampl
aluminum
oil
emuls
form
longterm
tissu
depot
postul
caus
chronic
toxic
effect
howev
detect
chronic
toxic
determin
causal
relationship
extrem
difficult
imposs
due
long
delay
diseas
onset
environment
exposur
eg
immun
may
occur
decad
later
period
report
highlight
potenti
tempor
associ
immun
adjuv
vaccin
occurr
advers
event
needless
say
associ
may
repres
causat
need
establish
individu
case
exampl
associ
includ
report
macrophag
myofasci
patient
previous
receiv
vaccin
contain
aluminum
adjuv
narcolepsi
children
immun
pandem
influenza
vaccin
contain
squalen
emuls
adjuv
notabl
incid
report
advers
event
within
context
total
immun
popul
often
extrem
small
thu
vaccineattribut
risk
develop
narcolepsi
estim
vaccin
finnish
express
ration
total
immun
finnish
popul
irrespect
age
would
closer
although
preval
macrophag
myofasci
known
henri
mondor
hospit
identifi
special
syndrom
report
case
diagnos
year
period
need
put
perspect
total
french
popul
number
million
henc
media
antivaccin
lobbi
group
often
bias
toward
report
focus
rare
vaccin
advers
effect
gener
ignor
extrem
larg
denomin
total
immun
popul
case
drawn
problem
rare
vaccin
advers
event
regulatori
perspect
often
extrem
difficult
imposs
ever
establish
proof
causal
henc
best
done
assess
whether
causat
plausibl
use
knowledg
particular
vaccin
adjuv
mechan
action
even
situat
causat
held
probabl
case
specif
pandem
influenza
vaccin
childhood
narcolepsi
still
possibl
identifi
vaccin
compon
respons
rel
contribut
antigen
adjuv
present
whilst
anim
model
might
seem
best
solut
test
causat
advers
reaction
direct
extrapol
model
difficult
guarante
accur
reflect
human
context
henc
vaccin
adjuv
safeti
assess
subject
natur
indic
urgent
need
research
method
better
assess
adjuv
safeti
investig
rare
advers
event
may
possibl
vaccin
andor
adjuv
relat
better
understand
adjuv
safeti
issu
use
individu
examin
adjuv
human
data
avail
almost
centuri
aluminum
salt
maintain
domin
adjuv
human
vaccin
reflect
fact
aluminum
adjuv
extrem
effect
enhanc
antibodi
respons
well
toler
caus
pyrexia
strongest
safeti
record
human
adjuv
henc
aluminum
adjuv
remain
gold
standard
new
adjuv
need
compar
new
adjuv
must
prove
provid
better
protect
toler
safeti
prefer
compar
aluminum
adjuv
prove
extrem
hard
achiev
explain
aluminum
ongo
domin
aluminum
action
initi
thought
due
local
antigen
depot
effect
situat
recogn
complex
inflammasom
activ
interleukin
il
product
cell
necrosi
dna
releas
activ
damp
pamp
receptor
propos
contribut
action
metal
salt
includ
iron
beryllium
also
induc
lysosom
ruptur
phagocyt
cell
death
share
alum
adjuv
activ
suggest
induct
cell
death
common
featur
adjuv
base
metal
salt
propens
kill
phagocyt
may
help
explain
alum
inabl
induc
robust
cellular
immun
live
antigen
present
cell
requir
effici
antigen
crosspresent
cell
aluminum
adjuv
suffer
number
minor
toxic
potenti
explain
mechan
action
exampl
aluminum
induc
inject
site
pain
tender
may
reflect
cell
necrosi
induct
inflammasom
activ
product
aluminum
salt
propens
induc
cell
death
inflammasom
activ
could
also
explain
subject
develop
persist
lump
granuloma
inject
site
aluminum
adjuv
also
induc
contact
dermat
aluminum
fraction
immun
subject
aluminum
adjuvantcontain
vaccin
caus
postimmun
headach
arthralgia
myalgia
could
reflect
alum
propens
induc
administr
human
subject
reproduc
symptom
posit
side
aluminum
adjuv
rare
caus
sever
local
reaction
normal
associ
system
inflammatori
problem
pyrexia
potenti
issu
aluminum
adjuv
propens
induc
immun
bia
increas
eosinophil
ige
product
therebi
increas
risk
allergi
anaphylaxi
phenomenon
reproduc
murin
ovalbumin
sensit
model
sensit
repeat
immun
ovalbumin
plu
aluminum
adjuv
induc
suscept
allerg
asthma
lethal
anaphylaxi
upon
subsequ
ovalbumin
reexposur
aluminum
adjuvantassoci
allerg
sensit
prevent
receptor
knockout
mice
administr
cpg
oligonucleotid
indic
allergi
sensit
due
aluminum
adjuv
excess
bia
immun
bia
may
particular
problem
children
alreadi
geneticallybias
toward
excess
immun
respons
allergi
excess
bia
particular
problem
vaccin
virus
respiratori
syncyti
viru
rsv
sar
coronaviru
sar
aluminumadjuv
vaccin
shown
increas
risk
lung
eosinophil
immunopatholog
upon
viru
infect
mechan
thought
contribut
death
children
administ
experiment
formalininactiv
aluminumadjuv
rsv
vaccin
becam
infect
rsv
mous
model
sar
lung
eosinophil
immunopatholog
could
prevent
anim
immun
sar
antigen
combin
polar
delta
inulin
adjuv
place
aluminum
adjuv
suggest
adjuv
share
bia
aluminum
would
safer
use
vaccin
pathogen
rsv
sar
excess
bia
could
otherwis
result
detriment
immun
respons
respons
viral
infect
cat
dog
ferret
aluminum
adjuv
caus
local
chronic
granulomat
lesion
progress
malign
fibrosarcoma
similar
tumor
seen
aluminumimmun
human
known
howev
aluminum
adjuv
human
report
caus
chronic
granulomat
inflamm
call
macrophag
myofasci
mmf
symptom
mmf
syndrom
includ
myalgia
arthralgia
mark
asthenia
muscl
weak
fever
abnorm
find
mmf
patient
includ
elev
creatin
kinas
erythrocyt
sediment
rate
plu
myopath
electromyograph
muscl
biopsi
mmf
patient
shown
infiltr
sheet
macrophag
granular
periodicacidschiff
posit
content
aluminum
deposit
demonstr
lesion
energi
dispers
xray
microanalysi
syndrom
hypothes
due
persist
vaccinederiv
aluminum
tissu
deposit
result
perpetu
cycl
macrophag
ingest
alum
intracellular
lysosom
ruptur
phagocyt
death
ingest
alumcontain
dead
phagocyt
newli
recruit
macrophag
lead
chronic
inflammatori
reaction
although
link
muscular
mmf
lesion
describ
mmf
symptom
remain
contenti
area
debat
mmf
patient
report
demonstr
neurolog
manifest
resembl
multipl
sclerosi
sinc
origin
descript
case
mmf
diagnos
franc
sporad
case
report
countri
number
need
put
perspect
total
immun
french
popul
like
number
million
current
treatment
surgic
resect
aluminum
origin
muscl
inject
site
interestingli
symptom
mmf
close
resembl
mucklewel
syndrom
caus
inherit
mutat
result
constitut
inflammasom
activ
aluminum
adjuv
known
also
induc
inflammasom
activ
possibl
specul
mmf
might
occur
individu
also
suscept
chronic
inflammasom
activ
mmf
could
essenti
repres
lowgrad
acquir
form
mucklewel
syndrom
plausibl
mechan
given
aluminum
known
molecular
action
gacv
accept
mmf
lesion
contain
aluminum
salt
identifi
histopatholog
examin
found
site
previou
vaccin
aluminumcontain
vaccin
conclud
evid
suggest
result
clinic
ill
diseas
gacv
recommend
understand
mmf
addit
research
studi
need
undertaken
evalu
clinic
epidemiolog
immunolog
basic
scienc
aspect
diseas
antiphospholipid
syndrom
autoimmun
disord
manifest
elev
titer
antiphospholid
antibodi
arteri
venou
thromboembol
event
recurr
spontan
abort
thrombocytopenia
tetanu
toxoid
hyperimmun
abl
reproduc
antiphospholipid
syndrom
ap
mice
correl
induct
crossreact
low
affin
glycoprotein
gpi
antibodi
mice
tetanu
toxoid
hyperimmun
aluminum
adjuv
glycerol
result
increas
low
affin
gpi
igg
antibodi
decreas
matern
fecund
consist
aluminum
adjuv
critic
compon
model
antiphospholipid
syndrom
extent
aluminumadjuv
tetanu
vaccin
might
contribut
rare
human
case
antiphospholipid
syndrom
known
high
aluminum
level
bodi
predomin
affect
brain
bone
tissu
caus
fatal
neurolog
syndrom
dialysisassoci
dementia
cerebr
aluminum
accumul
also
observ
alzheim
diseas
aluminum
exposur
pediatr
parenter
nutrit
shown
impair
bone
miner
delay
neurolog
develop
low
dose
aluminum
renal
excret
condit
reduc
renal
function
aluminum
accumul
bodi
becom
toxic
furthermor
environment
aluminum
load
greater
past
addit
load
multipl
alumbas
vaccin
must
ad
research
use
aluminum
oxyhydroxid
particl
label
fluoresc
function
nanodiamond
confirm
day
postimmun
brain
mice
contain
averag
solid
aluminum
particl
parallel
studi
vitro
confirm
aluminum
adjuv
toxic
neuron
cell
cultur
consist
mous
studi
show
neurotox
effect
includ
neural
apoptosi
motor
behavior
deficit
aluminum
adjuv
contribut
cumul
dose
aluminum
adjuv
might
make
human
chronic
disord
alzheim
diseas
chronic
bone
diseas
simpli
unknown
warrant
thorough
investig
particular
parenterallyadminist
aluminum
particl
behav
differ
bodi
solubl
aluminum
particl
transport
unusu
site
brain
phagocytosi
wherea
solubl
aluminum
ion
current
exposur
limit
set
easili
excret
kidney
gacv
character
studi
suggest
advers
effect
aluminum
adjuv
human
serious
flaw
unfortun
fail
comment
valid
otherwis
anim
toxicolog
data
potenti
relev
human
immun
advers
find
alum
adjuv
would
clearli
seriou
ramif
view
current
lack
adjuv
altern
overwhelm
public
health
benefit
current
vaccin
contain
aluminum
adjuv
particularli
develop
countri
death
vaccineprevent
infecti
diseas
remain
high
henc
high
standard
proof
requir
claim
aluminum
adjuv
toxic
could
endors
riskbenefit
inclus
alum
adjuv
vaccin
absenc
viabl
altern
remain
overwhelmingli
posit
import
note
form
aluminum
adjuv
necessarili
exampl
report
mmf
larg
link
use
aluminum
hydroxid
may
reflect
fact
interstiti
fluid
contain
organ
acid
alphahydroxi
carboxyl
acid
abl
chelat
aluminum
react
readili
aluminum
phosphat
aluminum
hydroxid
result
three
time
aluminum
excret
rabbit
vaccin
aluminum
phosphat
aluminum
hydroxid
much
longer
tissu
resid
time
also
suggest
monkey
studi
histopatholog
lesion
similar
human
mmf
lesion
still
present
month
aluminum
hydroxideadjuv
vaccin
administr
versu
month
aluminum
phosphat
studi
none
immun
monkey
develop
clinic
symptom
despit
presenc
mmflike
lesion
although
still
exclud
possibl
clinic
symptom
associ
mmf
lesion
human
subject
genet
otherwis
predispos
develop
rare
syndrom
class
adjuv
includ
wide
spectrum
oilinwat
waterinoil
emuls
water
oil
adjuv
complet
freund
adjuv
cfa
rank
reactogen
known
adjuv
henc
unsuit
human
use
oilinwat
emuls
lower
although
still
signific
reactogen
includ
squalenebas
adjuv
variou
montanid
oil
adjuv
liposom
adjuv
compos
cation
liposom
vehicl
dimethyldioctadecylammonium
dda
stabil
trehalos
glycolipid
synthet
variant
mycobacteri
cord
factor
mechan
action
oil
emuls
reflect
abil
induc
strong
inflammatori
reaction
inject
site
local
cell
death
lead
product
damp
inflammasom
activ
oil
compon
also
form
potenti
longterm
depot
entrap
antigen
slow
system
releas
local
toxic
oil
emuls
includ
sever
inject
site
pain
due
local
tissu
damag
follow
sever
inflammatori
reaction
case
may
progress
format
steril
granuloma
ulcer
inject
site
overal
emuls
adjuv
tend
high
end
local
reactogen
scale
henc
ideal
prophylact
vaccin
use
particularli
pediatr
popul
oil
emuls
also
caus
gener
system
symptom
includ
fever
headach
malais
nausea
diarrhea
arthralgia
myalgia
lethargi
reflect
induct
inflamm
major
recur
concern
potenti
associ
oil
emuls
adjuv
autoimmun
diseas
induct
seen
anim
fish
model
singl
intraderm
inject
rang
oil
emuls
includ
squalen
emuls
induc
adjuv
arthriti
suscept
murin
rat
model
adjuv
arthriti
transferr
use
cell
inhibit
antitcel
antibodi
associ
increas
express
proinflammatori
cytokin
includ
drain
lymph
node
indic
oil
emuls
adjuv
activ
autoreact
arthritogen
cell
administr
cfa
ifa
alon
mice
also
induc
experiment
autoimmun
hepat
suscept
oil
emulsioninduc
autoimmun
diseas
close
link
genet
factor
theoret
risk
human
share
similar
genet
suscept
featur
model
could
similarli
prone
develop
adjuv
arthriti
lupu
autoimmun
hepat
uveiti
form
autoimmun
diseas
exposur
oil
emuls
adjuv
alon
combin
potent
innat
immun
activ
monophosphoryl
lipid
might
relev
adjuv
contain
squalen
tocopherol
contain
narcolepsyassoci
pandem
influenza
vaccin
caus
factor
trigger
narcolepsi
still
known
adjuv
could
play
major
role
increas
narcolepsi
seen
children
receiv
altern
unadjuv
vaccin
henc
could
hypothes
inflamm
induc
adjuv
could
contribut
break
selftoler
thought
play
major
role
autoimmun
disord
includ
multipl
sclerosi
rheumatoid
arthriti
psoriasi
experiment
allerg
enceph
eae
oil
emuls
potent
induc
inflammatori
cytokin
includ
given
import
break
selftoler
allow
cell
cross
blood
brain
barrier
could
explain
inflammatori
oil
emuls
adjuv
import
autoimmun
diseas
induct
anim
model
could
also
potenti
explain
mechan
wherebi
pandem
influenza
caus
narcolepsi
suscept
hla
children
saponin
tensoact
glycosid
contain
hydrophob
nucleu
triterpenoid
structur
carbohydr
chain
link
nucleu
quil
saponin
extract
deriv
bark
quillaja
saponaria
fraction
purifi
extract
revers
phase
chromatographi
induc
strong
humor
tcell
respons
saponin
adjuv
extens
util
experiment
therapeut
cancer
vaccin
deterg
effect
saponin
disrupt
cell
membran
result
moder
sever
inject
site
pain
muscl
cell
damag
death
caus
local
red
swell
granuloma
format
saponin
adjuv
also
caus
red
blood
cell
haemolysi
reflect
affin
saponin
cholesterol
present
erythrocyt
membran
make
saponin
less
toxic
mix
cholesterol
form
immunestimulatori
complex
iscom
iscom
particl
induc
less
hemolysi
still
induc
system
side
effect
includ
flulik
symptom
fever
malais
potenti
saponin
adjuv
trigger
autoimmun
human
known
elderli
human
subject
clinic
trial
experiment
alzheim
diseas
vaccin
develop
meningoenceph
although
role
adjuv
advers
reaction
known
tlr
adjuv
categori
cover
extrem
broad
spectrum
pathogenderiv
compound
includ
nucleic
acid
protein
lipopeptid
glycolipid
synthet
analogu
thereof
type
compound
like
differ
toxic
tlr
agonist
activ
inflammatori
transcript
factor
nfkb
tlr
adaptor
protein
trif
consequ
nfkb
activ
monocyt
product
pyrogen
inflammatori
cytokin
therebi
result
potenti
doselimit
inflamm
pyrexia
attempt
detoxifi
tlr
agonist
inevit
lead
loss
adjuv
activ
exemplifi
convers
highli
toxic
ligand
lipopolysaccharid
less
toxic
monophosphoryl
lipid
mpl
given
modest
potenc
mpl
need
combin
aluminum
adjuv
best
effect
exampl
combin
adjuv
mpl
aluminum
adjuv
includ
approv
prophylact
hepat
b
viru
hbv
vaccin
low
respond
renal
dialysi
patient
prophylact
human
papilloma
viru
vaccin
vaccin
local
reactogen
standard
aluminum
adjuv
vaccin
pain
inject
site
occur
versu
standard
vaccin
dose
consist
increas
vaccin
reactogen
due
mpl
compon
anim
model
adjuv
shown
caus
aberr
immun
respons
associ
toxic
exampl
inclus
agonist
intranas
influenza
vaccin
mice
caus
exacerb
ill
death
immun
anim
challeng
influenza
exacerb
lung
patholog
subsequ
found
due
agonist
induc
excess
respons
agonist
also
shown
abl
break
toler
induc
autoimmun
suscept
anim
model
exampl
agonist
like
inflammatori
agent
trehalos
dimycol
pristan
squalen
oil
potent
induc
inflammatori
arthriti
suscept
strain
howev
potenti
signific
find
human
safeti
known
rel
dose
use
human
adjuv
like
much
lower
use
anim
model
agonist
base
unmethyl
cpgcontain
oligonucleotid
cpg
also
develop
human
vaccin
adjuv
bind
cpg
lead
activ
nfkb
releas
inflammatori
cytokin
therebi
stimul
immun
respons
cpg
also
bind
directli
bcell
express
lead
bcell
prolifer
antibodi
secret
initi
develop
anticanc
use
cpg
shown
well
toler
inject
intraven
high
dose
cancer
subject
gener
phosphodiest
linkag
nativ
cpg
sequenc
consid
unsuit
vivo
use
rapidli
degrad
dnase
henc
synthet
phosphorothioatebackbon
almost
exclus
use
current
cpg
adjuv
human
develop
howev
phosphorothioatebackbon
shown
caus
increas
advers
effect
murin
model
includ
splenomegali
lymphoid
follicl
destruct
immunosuppress
last
year
phosphorothioatebackbon
cpg
adjuv
use
human
clinic
trial
broad
rang
vaccin
applic
infecti
diseas
hepat
b
influenza
malaria
anthrax
hiv
cancer
melanoma
nonsmal
cell
lung
cancer
allergi
rhiniti
ad
aluminumadjuv
hepat
b
vaccin
seroprotect
singl
dose
seen
subject
versu
none
receiv
aluminumadjuv
vaccin
alon
advers
event
includ
inject
site
reaction
flulik
symptom
headach
frequent
cpg
group
predominantli
mild
moder
intens
iss
synthet
agonist
oligonucleotid
use
adjuv
vaccin
develop
hepat
b
prophylaxi
vaccin
contain
iss
promot
faster
seroprotect
compar
engerix
b
vaccin
symptom
local
system
reactogen
first
day
postimmun
significantli
differ
aluminumadjuv
control
vaccin
although
studi
report
higher
rate
inject
site
reaction
group
due
occurr
case
autoimmun
wegen
granulomatosi
subject
receiv
trial
potenti
autoimmun
event
monitor
subsequ
trial
newonset
autoimmun
event
case
hypothyroid
vitiligo
occur
group
none
compar
group
although
due
small
number
random
ratio
differ
signific
nevertheless
fda
vaccin
relat
biolog
product
advisori
committe
review
biolog
licens
applic
heplisav
deem
still
insuffici
data
adequ
support
safeti
heplisav
tlrbase
adjuv
approach
test
preliminari
human
trial
ligand
flagellin
sinc
flagellin
protein
conveni
express
fusion
protein
antigen
success
appli
use
influenza
hemagglutininbas
vaccin
globular
head
domain
asolomon
influenza
viru
fuse
flagellin
induc
function
antibodi
respons
common
local
advers
event
pain
inject
site
mild
moder
intens
system
symptom
includ
fatigu
headach
subject
receiv
higher
antigen
dose
moder
sever
system
symptom
accompani
substanti
increas
serum
creactiv
protein
crp
consist
mark
inflammatori
respons
clinic
trial
also
conduct
fusion
protein
compris
copi
ectodomain
influenza
matrix
protein
fuse
flagellin
follow
first
inject
higher
dose
selflimit
sever
symptom
note
subject
associ
elev
crp
level
believ
mediat
cytokin
releas
henc
major
challeng
pose
flagellinbas
adjuv
approach
also
mirror
ligand
adjuv
whether
possibl
titrat
dose
achiev
suffici
vaccin
immunogen
one
hand
avoid
excess
reactogen
inflamm
major
categori
mucos
adjuv
includ
cholera
toxin
ct
escherichia
coli
heatlabil
toxin
lt
mutat
variant
thereof
mucos
adjuv
thought
work
via
abil
bind
distinct
gangliosid
cell
surfac
receptor
stimul
adpribosyl
activ
therebi
activ
adenyl
cyclas
increas
intracellular
camp
ct
complex
rang
adjuv
activ
promot
costimulatori
molecul
express
express
therebi
enhanc
respons
bcell
isotypeswitch
iga
igg
product
suppress
interferon
regulatori
product
cell
ligand
express
therebi
suppress
respons
gut
epitheli
cell
camp
elev
lead
secret
electrolyt
water
gut
lumen
sever
diarrhea
major
doselimit
toxic
unmodifi
ct
adjuv
whilst
detoxifi
version
ct
lt
develop
human
develop
enterotoxinbas
mucos
adjuv
sever
set
back
follow
clinic
influenza
vaccin
trial
use
detoxifi
ltbase
adjuv
intranas
inactiv
vaccin
caus
facial
nerv
palsi
small
number
subject
polysaccharid
includ
polyglucan
polyfructan
mannan
share
benefit
biocompat
biodegrad
potenti
use
immunolog
activ
polysaccharid
adjuv
separ
two
class
base
whether
activ
nfkb
henc
proinflammatori
dextran
zymosan
mannan
nt
activ
nfkb
noninflammatori
delta
inulin
polysaccharid
adjuv
activ
nfkb
inflamm
behav
like
emuls
adjuv
abl
induc
adjuv
arthriti
suscept
anim
model
polysaccharid
adjuv
known
delta
inulin
enhanc
humor
cellular
immun
respons
wide
varieti
viral
bacteri
antigen
without
evid
inflammatori
side
effect
delta
inulin
adjuv
safe
administ
pregnant
dam
mous
pup
abl
induc
protect
singl
influenza
vaccin
dose
contrast
squalen
emuls
adjuv
fail
protect
pup
even
two
vaccin
dose
delta
inulin
adjuv
enhanc
vaccin
immunogen
well
toler
human
clinic
trial
hepat
b
pandem
influenza
bee
sting
allergi
vaccin
inflamm
key
mechan
behind
adjuvantassoci
toxic
includ
autoimmun
diseas
induct
noninflammatori
adjuv
delta
inulin
may
help
avoid
toxic
safeti
issu
possibl
warrant
explor
could
provid
rout
develop
safer
bettertoler
adjuv
respect
safeti
polysaccharid
particularli
particul
form
activ
complement
caus
anaphylatoxin
releas
basophil
mast
cell
activ
potenti
symptom
anaphylactoid
shock
gener
howev
complement
activ
suffici
induc
anaphylactoid
shock
seen
intraven
intramuscular
subcutan
inject
furthermor
mani
polysaccharid
includ
dextran
delta
inulin
bind
plasma
lipoprotein
may
therebi
provid
neg
feedback
downstream
complement
activ
new
class
adjuv
base
glycolipid
bind
immun
receptor
therebi
activ
nkt
cell
lead
cytokin
product
enhanc
vaccin
respons
whilst
character
nkt
cell
agonist
galactosyl
ceramid
extens
test
human
potenti
anticanc
therapi
human
data
use
vaccin
adjuv
yet
avail
despit
promis
data
adjuv
potenc
anim
studi
howev
synthet
analogu
galactosyl
ceramid
test
phase
human
trial
dose
abil
enhanc
antibodi
respons
hepat
b
vaccin
known
toxic
aris
activ
nkt
cell
liver
high
dose
liver
toxic
seen
mice
moder
elev
hepat
one
four
monkey
develop
elev
transaminas
highest
dose
test
clinic
trial
undertaken
healthi
adult
subject
peripher
blood
nkt
cell
activ
increas
circulatori
seen
postimmun
increas
antibodi
titer
seen
day
compar
antigen
alon
consist
adjuv
effect
howev
subject
receiv
seriou
treatmentemerg
advers
event
major
increas
hepat
transaminas
ast
alt
last
sever
week
postimmun
withdrawn
studi
conclud
formul
safe
human
use
due
nkt
cell
activ
result
hepatotox
aluminum
squalen
oil
emuls
adjuv
alreadi
broad
human
use
shown
induc
major
advers
effect
anim
model
although
relev
find
human
remain
unknown
henc
data
model
larg
ignor
safeti
determin
made
new
vaccin
contain
grandfath
adjuv
regul
instead
focu
vaccin
safeti
data
collect
rabbit
guinea
pig
togeth
data
human
clinic
trial
assess
vaccin
safeti
notabl
remain
need
better
scientif
explan
specif
anim
model
data
show
adjuv
toxic
relev
human
use
exampl
know
mani
year
squalen
oil
emuls
either
alon
formul
relev
antigen
induc
autoimmun
condit
eg
adjuv
arthriti
geneticallysuscept
anim
henc
consum
might
reason
ask
anim
toxic
data
predict
possibl
adjuv
caus
autoimmun
diseas
human
subject
also
genet
suscept
current
good
answer
question
given
narcolepsi
case
associ
use
pandem
influenza
vaccin
contain
squalen
oil
emuls
adjuv
reason
ask
whether
adjuv
test
propens
induc
autoimmun
diseas
geneticallysuscept
anim
model
even
influenza
antigen
vaccin
turn
respons
induc
narcolepsi
eg
process
antigen
mimicri
still
plausibl
adjuv
play
role
break
selftoler
inflammatori
adjuv
critic
diseas
induct
model
experiment
allerg
encephalomyel
one
possibl
mechan
worth
investig
whether
adjuv
induc
excess
respons
lead
open
bloodbrain
gate
autoreact
cell
induc
influenza
antigen
mimicri
henc
toxic
may
depend
adjuv
antigen
ingredi
combin
togeth
genet
background
age
popul
immun
highlight
problem
tri
assess
adjuv
safeti
use
tradit
test
method
design
assess
small
molecul
drug
organ
toxic
rather
potenti
immunolog
toxic
absenc
agreement
appropri
assay
screen
potenti
immunolog
toxic
exist
adjuv
notabl
aluminum
squalen
oil
emuls
continu
approv
grandfath
basi
leav
extrem
high
barrier
entri
new
adjuv
remov
obstacl
introduct
new
adjuv
need
adjuv
research
includ
research
mechan
adjuv
toxic
therebi
hope
allow
develop
better
vivo
vitro
model
adjuv
safeti
assess
whilst
preced
section
discuss
adjuv
safeti
assess
gener
section
focu
safeti
aspect
specif
adjuv
current
clear
type
preclin
test
might
undertaken
prove
adjuv
immunolog
safe
respect
import
distinguish
immunolog
safeti
ie
risk
induc
trigger
exacerb
immun
diseas
suscept
individu
toxicolog
safeti
assess
current
good
laboratori
practic
glp
safeti
test
use
healthi
anim
glp
safeti
test
design
measur
system
safeti
context
potenti
direct
organ
damag
substanc
method
test
relev
small
molecul
drug
adjuv
vaccin
compon
like
nontox
immun
respons
gener
may
short
longterm
advers
effect
either
spontan
upon
exposur
relev
pathogen
new
vaccin
includ
contain
new
adjuv
need
pass
standard
toxicolog
test
issu
potenti
immunolog
toxic
toohard
basket
henc
agreement
might
appropri
predict
test
immunolog
toxic
adjuv
vaccin
situat
made
complex
test
immunolog
toxic
would
need
undertaken
suscept
anim
may
requir
substitut
antigen
andor
adjuv
purpos
assess
safeti
compon
separ
current
regulatori
guidelin
indic
vaccin
adjuv
assess
approv
right
independ
vaccin
antigen
notabl
narcolepsi
influenza
immun
affect
hla
posit
children
similarli
autoimmun
diseas
affect
specif
human
subpopul
eg
ankylos
spondyl
hla
individu
multipl
sclerosi
hla
individu
type
diabet
hla
individu
henc
immunolog
safeti
easili
assess
anim
strain
genet
suscept
particular
autoimmun
diseas
rare
except
eg
adjuv
arthriti
test
immunolog
toxic
also
requir
adjuv
test
combin
one
selfantigen
thu
exampl
eae
induc
administ
neuron
selfantigen
eg
myelin
basic
protein
mbp
togeth
proinflammatori
adjuv
eg
cfa
genet
prone
anim
henc
eae
model
could
use
assess
immunolog
safeti
particular
adjuv
combin
mbp
administ
suscept
anim
eae
induc
particular
adjuv
might
provid
reassur
adjuv
unlik
break
selftoler
induc
autoimmun
diseas
even
inadvert
formul
selfantigen
mimic
hand
exampl
neither
aluminum
delta
inulin
adjuv
abl
induc
eae
even
formul
mbp
use
immun
suscept
anim
unpublish
data
bigger
problem
candid
adjuv
induc
eae
model
risk
adjuv
inadvert
formul
vaccin
antigen
turn
later
selfantigen
mimic
might
happen
narcolepsyassoci
pandem
influenza
vaccin
would
seem
prefer
includ
prophylact
vaccin
adjuv
demonstr
easili
break
selftoler
nevertheless
adjuv
may
ideal
use
cancer
vaccin
abil
break
selftoler
might
virtu
eae
adjuv
arthriti
model
teach
us
induct
autoimmun
diseas
depend
exposur
genet
suscept
individu
relev
selfantigen
togeth
inflammatori
adjuv
abl
break
selftoler
simpli
avoid
inclus
prophylact
vaccin
inflammatori
adjuv
abl
break
selftoler
risk
autoimmun
diseas
therebi
reduc
even
vaccin
includ
selfantigen
mimic
addit
eae
mani
wellestablish
anim
model
vaccineinduc
autoimmun
diseas
includ
thyroid
arthriti
uveiti
could
use
screen
candid
adjuv
formul
potenti
immunolog
toxic
due
abil
break
selftoler
predict
highli
proinflammatori
adjuv
oil
emuls
would
fail
test
like
cfa
shown
induc
autoimmun
diseas
relev
model
similarli
although
regulatori
bodi
current
requir
test
new
adjuv
potenti
ige
induct
allergyexacerb
would
seem
sensibl
requir
test
new
adjuv
relev
allergi
induct
model
assess
aluminum
propens
induc
igemedi
anaphylaxi
anoth
issu
adjuv
safeti
test
adjuv
tlr
ligand
may
speci
differ
relev
receptor
downstream
pathway
andor
tissu
distribut
may
make
difficult
fulli
assess
safeti
absenc
human
anim
model
situat
would
use
identifi
vitro
surrog
adjuv
toxic
use
human
cell
line
primari
cell
readout
potenc
cytokin
induct
unfortun
vitro
approach
may
limit
valu
recapitul
complex
adjuv
action
vivo
exampl
mani
adjuv
includ
aluminum
littl
effect
cytokin
product
vitro
yet
potent
adjuv
effect
vivo
furthermor
toxic
may
occur
distant
unexpect
tissu
compart
hepatotox
seen
inject
nkt
cell
agonist
henc
assess
adjuv
potenc
toler
safeti
continu
requir
vivo
test
given
vaccin
advers
effect
may
affect
rare
individu
stochast
manner
underli
genet
suscept
predict
anim
model
need
abl
recapitul
factor
necessit
research
natur
human
suscept
adjuv
toxic
tool
includ
whole
genom
sequenc
gene
express
array
deep
sequenc
approach
readili
avail
start
address
question
medic
intervent
complet
without
risk
henc
human
medicin
includ
vaccin
approv
regul
base
riskbenefit
principl
interest
public
protect
regul
food
drug
administr
whose
role
approv
vaccin
proven
benefit
outweigh
measur
risk
assess
vaccin
riskbenefit
complex
therapeut
intervent
benefit
vaccin
accru
popul
herd
immun
risk
advers
reaction
suffer
individu
potenti
rais
complex
ethic
issu
henc
percept
riskbenefit
individu
level
ie
want
immun
benefit
justifi
risk
vaccin
reaction
sometim
difficult
reconcil
riskbenefit
assess
public
health
level
ie
allow
mani
individu
immun
herd
immun
lost
seriou
infecti
diseas
outbreak
may
eventu
henc
polici
maker
vaccin
recipi
might
differ
percept
immun
riskbenefit
also
like
shape
public
view
adjuv
riskbenefit
particularli
situat
adjuv
unadjuv
vaccin
avail
indic
exampl
approv
season
influenza
vaccin
europ
contain
squalen
emuls
adjuv
vast
major
influenza
vaccin
use
europ
adjuv
factor
influenc
consum
practition
util
adjuv
versu
unadjuv
influenza
vaccin
could
therebi
use
area
studi
adjuv
season
influenza
vaccin
current
avail
us
could
potenti
reflect
differ
regulatori
consum
view
across
contin
influenza
pandem
adjuv
unadjuv
pandem
vaccin
util
europ
consum
alway
given
choic
regard
vaccin
use
contrast
unadjuv
pandem
vaccin
use
us
impos
lack
consum
choic
european
countri
may
act
reinforc
neg
percept
adjuv
vaccin
particularli
subsequ
reveal
squaleneadjuv
vaccin
use
pandem
associ
increas
risk
childhood
narcolepsi
given
potenti
public
apprehens
around
term
adjuv
need
research
identifi
sourc
fear
develop
strategi
allevi
origin
consum
apprehens
surround
adjuv
like
multifactori
potenti
contributor
gener
mistrust
govern
public
health
polici
percept
lack
choic
media
coverag
rare
advers
reaction
confus
issu
aluminum
thiomers
vaccin
excipi
cite
paper
role
adjuv
oil
emuls
autoimmun
diseas
anim
model
respect
latter
scientist
know
anim
model
find
may
alway
translat
human
reflect
say
mice
lie
howev
absenc
adequ
educ
mani
consum
unlik
appreci
point
may
place
undu
emphasi
data
make
riskbenefit
assess
respect
adjuv
vaccin
also
import
research
undertaken
better
understand
advers
effect
anim
model
relat
human
context
even
adjuv
causal
confirm
rare
vaccin
advers
event
creat
disclosur
dilemma
name
risk
rare
vaccineassoci
advers
event
public
given
consum
like
react
interest
public
health
possibl
rare
advers
event
downplay
avoid
damag
immun
campaign
easi
question
answer
assist
success
introduct
new
adjuv
without
risk
consum
backlash
would
benefici
better
understand
public
percept
regard
adjuv
could
allow
consum
educ
campaign
design
address
misunderstand
concern
henc
alongsid
greater
research
mechan
underli
potenti
adjuvantassoci
advers
reaction
research
also
need
consum
percept
adjuv
polici
improv
immun
rate
could
easili
backfir
care
research
whilst
argu
societi
right
respons
establish
law
regul
choic
framework
discourag
vaccin
refus
mandatori
action
reduc
consum
choic
need
consid
care
anoth
question
role
bodi
global
advisori
committe
vaccin
safeti
adjud
vaccin
adjuv
safeti
arguabl
primari
role
bodi
defend
vaccin
use
develop
countri
riskbenefit
immun
vastli
differ
develop
countri
infecti
diseas
far
less
preval
old
age
chronic
diseas
far
preval
notabl
case
consid
committe
refer
made
lack
data
inadequ
well
conduct
control
studi
confirm
possibl
vaccin
risk
highlight
remark
lack
research
vaccin
adjuv
safeti
issu
despit
fact
research
fit
within
framework
global
regulatori
scienc
agenda
vaccin
paper
highlight
inher
difficulti
assess
adjuv
safeti
poor
state
knowledg
mechan
underli
potenti
adjuv
toxic
even
aluminum
adjuv
widespread
human
use
almost
centuri
given
billion
subject
still
unansw
question
regard
mechan
action
potenti
connect
condit
macrophag
myofasci
alzheim
diseas
thing
riskfre
vaccin
risk
immedi
sever
advers
reaction
extrem
low
modern
vaccin
consum
high
confid
safeti
avail
vaccin
facilit
introduct
new
adjuv
import
consum
educ
better
regard
vaccin
riskbenefit
assess
given
vital
import
adjuv
modern
vaccin
addit
resourc
need
support
research
better
understand
adjuv
action
might
relat
adjuv
toxic
new
adjuv
continu
need
improv
vaccin
potenc
without
compromis
toler
safeti
attract
hypothesi
warrant
explor
concept
noninflammatori
adjuv
abl
enhanc
vaccin
potenc
avoid
reactogen
safeti
issu
